Literature DB >> 25281742

The Eph tyrosine kinase receptors EphB2 and EphA2 are novel proteolytic substrates of tissue factor/coagulation factor VIIa.

Oskar Eriksson1, Margareta Ramström2, Katarina Hörnaeus2, Jonas Bergquist2, Dariush Mokhtari1, Agneta Siegbahn3.   

Abstract

Tissue factor (TF) binds the serine protease factor VIIa (FVIIa) to form a proteolytically active complex that can trigger coagulation or activate cell signaling. Here we addressed the involvement of tyrosine kinase receptors (RTKs) in TF/FVIIa signaling by antibody array analysis and subsequently found that EphB2 and EphA2 of the Eph RTK family were cleaved in their ectodomains by TF/FVIIa. We used N-terminal Edman sequencing and LC-MS/MS analysis to characterize the cleaved Eph isoforms and identified a key arginine residue at the cleavage site, in agreement with the tryptic serine protease activity of FVIIa. Protease-activated receptor 2 (PAR2) signaling and downstream coagulation activity was non-essential in this context, in further support of a direct cleavage by TF/FVIIa. EphB2 was cleaved by FVIIa concentrations in the subnanomolar range in a number of TF expressing cell types, indicating that the active cellular pool of TF was involved. FVIIa caused potentiation of cell repulsion by the EphB2 ligand ephrin-B1, demonstrating a novel proteolytical event to control Eph-mediated cell segregation. These results define Eph RTKs as novel proteolytical targets of TF/FVIIa and provide new insights into how TF/FVIIa regulates cellular functions independently of PAR2.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Coagulation Factor; Mass Spectrometry (MS); Receptor Tyrosine Kinase; Serine Protease; Tissue Factor

Mesh:

Substances:

Year:  2014        PMID: 25281742      PMCID: PMC4239594          DOI: 10.1074/jbc.M114.599332

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

Review 1.  Protein microarrays and proteomics.

Authors:  Gavin MacBeath
Journal:  Nat Genet       Date:  2002-12       Impact factor: 38.330

Review 2.  Concepts and consequences of Eph receptor clustering.

Authors:  Peter W Janes; Eva Nievergall; Martin Lackmann
Journal:  Semin Cell Dev Biol       Date:  2012-01-12       Impact factor: 7.727

3.  Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis.

Authors:  T A Drake; J H Morrissey; T S Edgington
Journal:  Am J Pathol       Date:  1989-05       Impact factor: 4.307

4.  Monoclonal antibody analysis of purified and cell-associated tissue factor.

Authors:  J H Morrissey; D S Fair; T S Edgington
Journal:  Thromb Res       Date:  1988-11-01       Impact factor: 3.944

5.  Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation.

Authors:  J H Morrissey; B G Macik; P F Neuenschwander; P C Comp
Journal:  Blood       Date:  1993-02-01       Impact factor: 22.113

6.  Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2.

Authors:  P W Bergum; A Cruikshank; S L Maki; C R Kelly; W Ruf; G P Vlasuk
Journal:  J Biol Chem       Date:  2001-01-03       Impact factor: 5.157

7.  Immunohistochemical identification of tissue factor in solid tumors.

Authors:  N S Callander; N Varki; L V Rao
Journal:  Cancer       Date:  1992-09-01       Impact factor: 6.860

8.  Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application.

Authors:  Brian P Fox; Raj P Kandpal
Journal:  Biochem Biophys Res Commun       Date:  2004-06-11       Impact factor: 3.575

9.  An anti-tissue factor monoclonal antibody which inhibits TF.VIIa complex is a potent anticoagulant in plasma.

Authors:  W Ruf; T S Edgington
Journal:  Thromb Haemost       Date:  1991-11-01       Impact factor: 5.249

10.  Regulation of angiogenesis by tissue factor cytoplasmic domain signaling.

Authors:  Mattias Belting; Michael I Dorrell; Staffan Sandgren; Edith Aguilar; Jasimuddin Ahamed; Andrea Dorfleutner; Peter Carmeliet; Barbara M Mueller; Martin Friedlander; Wolfram Ruf
Journal:  Nat Med       Date:  2004-04-18       Impact factor: 53.440

View more
  8 in total

Review 1.  Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis.

Authors:  Giovanni Cimmino; Plinio Cirillo
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

Review 2.  Targeting clotting proteins in cancer therapy - progress and challenges.

Authors:  Wolfram Ruf; Andrea S Rothmeier; Claudine Graf
Journal:  Thromb Res       Date:  2016-04       Impact factor: 3.944

Review 3.  Therapeutic potential of targeting the Eph/ephrin signaling complex.

Authors:  Nayanendu Saha; Dorothea Robev; Emilia O Mason; Juha P Himanen; Dimitar B Nikolov
Journal:  Int J Biochem Cell Biol       Date:  2018-10-19       Impact factor: 5.085

Review 4.  Proteolytic Cleavage of Receptor Tyrosine Kinases.

Authors:  Hao Huang
Journal:  Biomolecules       Date:  2021-04-29

5.  Cross-talk between the Tissue Factor/coagulation factor VIIa complex and the tyrosine kinase receptor EphA2 in cancer.

Authors:  Oskar Eriksson; Åsa Thulin; Anna Asplund; Geeta Hegde; Sanjay Navani; Agneta Siegbahn
Journal:  BMC Cancer       Date:  2016-05-31       Impact factor: 4.430

6.  Identifying and Analyzing Novel Epilepsy-Related Genes Using Random Walk with Restart Algorithm.

Authors:  Wei Guo; Dong-Mei Shang; Jing-Hui Cao; Kaiyan Feng; Yi-Chun He; Yang Jiang; ShaoPeng Wang; Yu-Fei Gao
Journal:  Biomed Res Int       Date:  2017-02-01       Impact factor: 3.411

Review 7.  Beyond thrombosis: the impact of tissue factor signaling in cancer.

Authors:  Dusten Unruh; Craig Horbinski
Journal:  J Hematol Oncol       Date:  2020-07-14       Impact factor: 17.388

Review 8.  Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy.

Authors:  Alan E Mast; Wolfram Ruf
Journal:  J Thromb Haemost       Date:  2022-03-27       Impact factor: 16.036

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.